Details of Disease

Disease Name

Cryptococcal meningitis

Cryptococcus neoformans caused infectious meningitis; Cryptococcus neoformans infectious meningitis

Definition

Meningeal inflammation produced by cryptococcus neoformans, an encapsulated yeast that tends to infect individuals with acquired immunodeficiency syndrome and other immunocompromised states. The organism enters the body through the respiratory tract, but symptomatic infections are usually limited to the lungs and nervous system. The organism may also produce parenchymal brain lesions (torulomas). Clinically, the course is subacute and may feature headache; nausea; photophobia; focal neurologic deficits; seizures; cranial neuropathies; and hydrocephalus. (From Adams et al., Principles of Neurology, 6th ed, pp721-2)

Disease Hierarchy

DISQ4DO4: Infectious meningitis

DISZVFGU: Fungal meningitis

DISDYDTK: Cryptococcosis

DIS1LBC6: Cryptococcal meningitis

Disease Identifiers

MONDO ID

MONDO_0005723

MESH ID

D016919

UMLS CUI

C0085436

MedGen ID

88410

HPO ID

HP:0032160

SNOMED CT ID

14232007

General Information of Disease (ID: DIS1LBC6)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Amphotericin B	DMTAJQE	Approved	Small molecular drug	[1]
Fluconazole	DMOWZ6B	Approved	Small molecular drug	[2]
Flucytosine	DM13VTW	Approved	Small molecular drug	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CYP51A1	TT67TDP	Limited	Biomarker	[4]
IL31RA	TT9HPX0	Strong	Biomarker	[5]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACTA1	OTOVGLPG	Strong	Biomarker	[6]
PMP2	OTKYV2NE	Strong	Altered Expression	[7]
------------------------------------------------------------------------------------

References

1	Amphotericin B FDA Label
2	Fluconazole FDA Label
3	Flucytosine FDA Label
4	The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis.J Antimicrob Chemother. 2018 Oct 1;73(10):2815-2822. doi: 10.1093/jac/dky242.
5	Molecular diagnosis of cryptococcal meningitis in cerebrospinal fluid: comparison of primer sets for Cryptococcus neoformans and Cryptococcus gattii species complex.Braz J Infect Dis. 2015 Jan-Feb;19(1):62-7. doi: 10.1016/j.bjid.2014.09.004. Epub 2014 Dec 16.
6	One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi.Clin Infect Dis. 2020 Jan 16;70(3):521-524. doi: 10.1093/cid/ciz454.
7	Characterization of host response to Cryptococcus neoformans through quantitative proteomic analysis of cryptococcal meningitis co-infected with HIV.Mol Biosyst. 2015 Sep;11(9):2529-40. doi: 10.1039/c5mb00187k.